First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study.

Br J Cancer · 2022 · PMC9130487 · PMID 35440667

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In particular, TT-B had a favourable effect on OS in women (HR 0.44; 95% CI: 0.26–0.76), in those who had not previously undergone surgical resection (HR 0.45; 95% CI: 0.23–0.88), in patients with mutant BRAF status (HR 0.17; 95% CI: 0.04–0.68) and in those with an ECOG PS of 2, although the latter did not reach statistical significance (HR 0.50; 95% CI: 0.2–1.26).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.